Skip to main content
Top
Published in: Pain and Therapy 2/2016

Open Access 01-12-2016 | Original Research

Health Care Utilization and Costs Associated with Nausea and Vomiting in Patients Receiving Oral Immediate-Release Opioids for Outpatient Acute Pain Management

Authors: Elizabeth Marrett, Winghan Jacqueline Kwong, Feride Frech, Chunlin Qian

Published in: Pain and Therapy | Issue 2/2016

Login to get access

Abstract

Introduction

Nausea and vomiting (NV) are common side effects of opioid use and limiting factors in pain management. This study sought to quantify the frequency of antiemetic prescribing and the impact of NV on health care resource utilization and costs in outpatients prescribed opioids for acute pain. The perspective was that of a commercial health plan.

Methods

Medical and pharmacy claims from IMS PharMetrics Plus were used to identify patients initiating opioid therapy with a prescription for an oxycodone-, hydrocodone- or codeine-containing immediate-release product for acute use (≤15-day supply) between October 1, 2013 and September 30, 2014. Patients with a medical claim for NV (International Classification of Diseases, Ninth Revision, Clinical Modification codes 787.0x), with or without an antiemetic prescription fill, were compared with patients with no NV claim or antiemetic prescription fill to assess differences in all-cause health care utilization and costs over 1 month. Propensity score matching (PSM) was used to adjust for between-group differences in baseline patient characteristics.

Results

The co-prescribing of opioids with antiemetic agents was 10.2%. After PSM (n = 45,790 per group), patients with NV claims had significantly more hospitalizations (11.5% vs 4.2%), emergency department visits (65.0% vs 12.1%), and physician office visits (85.2% vs 64.5%) compared with patients with no NV claims (all P < 0.0001). Mean total health care costs were higher among patients with a NV claim versus those without evidence of the side effect ($6290 vs $2309; P < 0.0001). Among patients with a recent hospitalization, patients with NV claims had higher rates of 30-day rehospitalization than those with no NV claims (24.4% vs 3.0%; P < 0.0001).

Conclusions

Among outpatients prescribed opioids for management of acute pain, co-prescribing with antiemetics was low, and the economic burden associated with NV was high. Efforts to prevent NV in patients receiving opioid therapy may improve patient outcomes and provide cost savings to the health care system.

Funding

Daiichi Sankyo, Inc.
Appendix
Available only for authorised users
Literature
1.
go back to reference Institute of Medicine Committee on Advancing Pain Research, Care, and Education. Relieving Pain in America: a blueprint for transforming prevention, care, education, and research. Washington, DC: The National Academies Press; 2011. Institute of Medicine Committee on Advancing Pain Research, Care, and Education. Relieving Pain in America: a blueprint for transforming prevention, care, education, and research. Washington, DC: The National Academies Press; 2011.
3.
go back to reference Kehlet H, Dahl JB. The value of “multimodal” or “balanced analgesia” in postoperative pain treatment. Anesth Analg. 1993;77(5):1048–56.CrossRefPubMed Kehlet H, Dahl JB. The value of “multimodal” or “balanced analgesia” in postoperative pain treatment. Anesth Analg. 1993;77(5):1048–56.CrossRefPubMed
4.
go back to reference Manchikanti L, Singh A. Therapeutic opioids: a ten-year perspective on the complexities and complications of the escalating use, abuse, and nonmedical use of opioids. Pain Physician. 2008;11(2 Suppl):S63–88.PubMed Manchikanti L, Singh A. Therapeutic opioids: a ten-year perspective on the complexities and complications of the escalating use, abuse, and nonmedical use of opioids. Pain Physician. 2008;11(2 Suppl):S63–88.PubMed
8.
go back to reference Jarzyna D, Jungquist CR, Pasero C, et al. American Society for Pain Management Nursing guidelines on monitoring for opioid-induced sedation and respiratory depression. Pain Manag Nurs. 2011;12(3):118–45.CrossRefPubMed Jarzyna D, Jungquist CR, Pasero C, et al. American Society for Pain Management Nursing guidelines on monitoring for opioid-induced sedation and respiratory depression. Pain Manag Nurs. 2011;12(3):118–45.CrossRefPubMed
9.
go back to reference Duensing L, Eksterowicz N, Macario A, Brown M, Stern L, Ogbonnaya A. Patient and physician perceptions of treatment of moderate-to-severe chronic pain with oral opioids. Curr Med Res Opin. 2010;26(7):1579–85.CrossRefPubMed Duensing L, Eksterowicz N, Macario A, Brown M, Stern L, Ogbonnaya A. Patient and physician perceptions of treatment of moderate-to-severe chronic pain with oral opioids. Curr Med Res Opin. 2010;26(7):1579–85.CrossRefPubMed
10.
go back to reference Sinatra R. Causes and consequences of inadequate management of acute pain. Pain Med. 2010;11(12):1859–71.CrossRefPubMed Sinatra R. Causes and consequences of inadequate management of acute pain. Pain Med. 2010;11(12):1859–71.CrossRefPubMed
12.
13.
go back to reference Gregorian RS Jr, Gasik A, Kwong WJ, Voeller S, Kavanagh S. Importance of side effects in opioid treatment: a trade-off analysis with patients and physicians. J Pain. 2010;11(11):1095–108.CrossRefPubMed Gregorian RS Jr, Gasik A, Kwong WJ, Voeller S, Kavanagh S. Importance of side effects in opioid treatment: a trade-off analysis with patients and physicians. J Pain. 2010;11(11):1095–108.CrossRefPubMed
14.
go back to reference Chung F, Lane R, Spraggs C, et al. Ondansetron is more effective than metoclopramide for the treatment of opioid-induced emesis in post-surgical adult patients. Eur J Anaesthesiol. 1999;16(10):669–77.CrossRefPubMed Chung F, Lane R, Spraggs C, et al. Ondansetron is more effective than metoclopramide for the treatment of opioid-induced emesis in post-surgical adult patients. Eur J Anaesthesiol. 1999;16(10):669–77.CrossRefPubMed
15.
16.
go back to reference Anastassopoulos KP, Chow W, Ackerman SJ, Tapia C, Benson C, Kim MS. Oxycodone-related side effects: impact on degree of bother, adherence, pain relief, satisfaction, and quality of life. J Opioid Manag. 2011;7(3):203–15.CrossRefPubMed Anastassopoulos KP, Chow W, Ackerman SJ, Tapia C, Benson C, Kim MS. Oxycodone-related side effects: impact on degree of bother, adherence, pain relief, satisfaction, and quality of life. J Opioid Manag. 2011;7(3):203–15.CrossRefPubMed
17.
go back to reference Varrassi G, Muller-Schwefe GH. The international CHANGE PAIN physician survey: does specialism influence the perception of pain and its treatment? Curr Med Res Opin. 2012;28(5):823–31.CrossRefPubMed Varrassi G, Muller-Schwefe GH. The international CHANGE PAIN physician survey: does specialism influence the perception of pain and its treatment? Curr Med Res Opin. 2012;28(5):823–31.CrossRefPubMed
18.
go back to reference Chang DJ, Desjardins PJ, Bird SR, et al. Comparison of rofecoxib and a multidose oxycodone/acetaminophen regimen for the treatment of acute pain following oral surgery: a randomized controlled trial. Curr Med Res Opin. 2004;20(6):939–49.CrossRefPubMed Chang DJ, Desjardins PJ, Bird SR, et al. Comparison of rofecoxib and a multidose oxycodone/acetaminophen regimen for the treatment of acute pain following oral surgery: a randomized controlled trial. Curr Med Res Opin. 2004;20(6):939–49.CrossRefPubMed
19.
go back to reference Kalso E, Edwards JE, Moore RA, McQuay HJ. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain. 2004;112(3):372–80.CrossRefPubMed Kalso E, Edwards JE, Moore RA, McQuay HJ. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain. 2004;112(3):372–80.CrossRefPubMed
20.
go back to reference Daniels S, Casson E, Stegmann JU, et al. A randomized, double-blind, placebo-controlled phase 3 study of the relative efficacy and tolerability of tapentadol IR and oxycodone IR for acute pain. Curr Med Res Opin. 2009;25(6):1551–61.CrossRefPubMed Daniels S, Casson E, Stegmann JU, et al. A randomized, double-blind, placebo-controlled phase 3 study of the relative efficacy and tolerability of tapentadol IR and oxycodone IR for acute pain. Curr Med Res Opin. 2009;25(6):1551–61.CrossRefPubMed
21.
go back to reference Park YB, Ha CW, Cho SD, et al. A randomized study to compare the efficacy and safety of extended-release and immediate-release tramadol HCl/acetaminophen in patients with acute pain following total knee replacement. Curr Med Res Opin. 2015;31(1):75–84.CrossRefPubMed Park YB, Ha CW, Cho SD, et al. A randomized study to compare the efficacy and safety of extended-release and immediate-release tramadol HCl/acetaminophen in patients with acute pain following total knee replacement. Curr Med Res Opin. 2015;31(1):75–84.CrossRefPubMed
22.
go back to reference Musclow SL, Bowers T, Vo H, Glube M, Nguyen T. Long-acting morphine following hip or knee replacement: a randomized, double-blind and placebo-controlled trial. Pain Res Manag. 2012;17(2):83–8.CrossRefPubMedPubMedCentral Musclow SL, Bowers T, Vo H, Glube M, Nguyen T. Long-acting morphine following hip or knee replacement: a randomized, double-blind and placebo-controlled trial. Pain Res Manag. 2012;17(2):83–8.CrossRefPubMedPubMedCentral
23.
go back to reference Pizzi LT, Toner R, Foley K, et al. Relationship between potential opioid-related adverse effects and hospital length of stay in patients receiving opioids after orthopedic surgery. Pharmacotherapy. 2012;32(6):502–14.CrossRefPubMed Pizzi LT, Toner R, Foley K, et al. Relationship between potential opioid-related adverse effects and hospital length of stay in patients receiving opioids after orthopedic surgery. Pharmacotherapy. 2012;32(6):502–14.CrossRefPubMed
24.
go back to reference Wheeler M, Oderda GM, Ashburn MA, Lipman AG. Adverse events associated with postoperative opioid analgesia: a systematic review. J Pain. 2002;3(3):159–80.CrossRefPubMed Wheeler M, Oderda GM, Ashburn MA, Lipman AG. Adverse events associated with postoperative opioid analgesia: a systematic review. J Pain. 2002;3(3):159–80.CrossRefPubMed
25.
go back to reference Moskovitz BL, Benson CJ, Patel AA, et al. Analgesic treatment for moderate-to-severe acute pain in the United States: patients’ perspectives in the Physicians Partnering Against Pain (P3) survey. J Opioid Manag. 2011;7(4):277–86.CrossRefPubMed Moskovitz BL, Benson CJ, Patel AA, et al. Analgesic treatment for moderate-to-severe acute pain in the United States: patients’ perspectives in the Physicians Partnering Against Pain (P3) survey. J Opioid Manag. 2011;7(4):277–86.CrossRefPubMed
26.
go back to reference Pergolizzi JV Jr, Raffa RB, Taylor R Jr. Treating acute pain in light of the chronification of pain. Pain Manag Nurs. 2014;15(1):380–90.CrossRefPubMed Pergolizzi JV Jr, Raffa RB, Taylor R Jr. Treating acute pain in light of the chronification of pain. Pain Manag Nurs. 2014;15(1):380–90.CrossRefPubMed
27.
go back to reference Shipton EA. The transition from acute to chronic post surgical pain. Anaesth Intensive Care. 2011;39(5):824–36.PubMed Shipton EA. The transition from acute to chronic post surgical pain. Anaesth Intensive Care. 2011;39(5):824–36.PubMed
28.
go back to reference Swegle JM, Logemann C. Management of common opioid-induced adverse effects. Am Fam Physician. 2006;74(8):1347–54.PubMed Swegle JM, Logemann C. Management of common opioid-induced adverse effects. Am Fam Physician. 2006;74(8):1347–54.PubMed
29.
go back to reference Moeller-Bertram T, Keltner J, Strigo IA. Pain and post traumatic stress disorder—review of clinical and experimental evidence. Neuropharmacology. 2012;62(2):586–97.CrossRefPubMed Moeller-Bertram T, Keltner J, Strigo IA. Pain and post traumatic stress disorder—review of clinical and experimental evidence. Neuropharmacology. 2012;62(2):586–97.CrossRefPubMed
30.
go back to reference Brennan F, Carr DB, Cousins M. Pain management: a fundamental human right. Anesth Analg. 2007;105(1):205–21.CrossRefPubMed Brennan F, Carr DB, Cousins M. Pain management: a fundamental human right. Anesth Analg. 2007;105(1):205–21.CrossRefPubMed
31.
go back to reference Kwong WJ, Diels J, Kavanagh S. Costs of gastrointestinal events after outpatient opioid treatment for non-cancer pain. Ann Pharmacother. 2010;44(4):630–40.CrossRefPubMed Kwong WJ, Diels J, Kavanagh S. Costs of gastrointestinal events after outpatient opioid treatment for non-cancer pain. Ann Pharmacother. 2010;44(4):630–40.CrossRefPubMed
32.
go back to reference Eberhart L, Koch T, Kranke P, Rusch D, Torossian A, Nardi-Hiebl S. Activity-based cost analysis of opioid-related nausea and vomiting among inpatients. J Opioid Manag. 2014;10(6):415–22.CrossRefPubMed Eberhart L, Koch T, Kranke P, Rusch D, Torossian A, Nardi-Hiebl S. Activity-based cost analysis of opioid-related nausea and vomiting among inpatients. J Opioid Manag. 2014;10(6):415–22.CrossRefPubMed
33.
go back to reference Kane-Gill SL, Rubin EC, Smithburger PL, Buckley MS, Dasta JF. The cost of opioid-related adverse drug events. J Pain Palliat Care Pharmacother. 2014;28(3):282–93.CrossRefPubMed Kane-Gill SL, Rubin EC, Smithburger PL, Buckley MS, Dasta JF. The cost of opioid-related adverse drug events. J Pain Palliat Care Pharmacother. 2014;28(3):282–93.CrossRefPubMed
34.
go back to reference Oderda GM, Evans RS, Lloyd J, et al. Cost of opioid-related adverse drug events in surgical patients. J Pain Symptom Manag. 2003;25(3):276–83.CrossRef Oderda GM, Evans RS, Lloyd J, et al. Cost of opioid-related adverse drug events in surgical patients. J Pain Symptom Manag. 2003;25(3):276–83.CrossRef
35.
go back to reference Oderda GM, Said Q, Evans RS, et al. Opioid-related adverse drug events in surgical hospitalizations: impact on costs and length of stay. Ann Pharmacother. 2007;41(3):400–6.CrossRefPubMed Oderda GM, Said Q, Evans RS, et al. Opioid-related adverse drug events in surgical hospitalizations: impact on costs and length of stay. Ann Pharmacother. 2007;41(3):400–6.CrossRefPubMed
36.
go back to reference Coluzzi F, Pappagallo M, National Initiative on Pain Control. Opioid therapy for chronic noncancer pain: practice guidelines for initiation and maintenance of therapy. Minerva Anestesiol. 2005;71(7–8):425–33.PubMed Coluzzi F, Pappagallo M, National Initiative on Pain Control. Opioid therapy for chronic noncancer pain: practice guidelines for initiation and maintenance of therapy. Minerva Anestesiol. 2005;71(7–8):425–33.PubMed
37.
go back to reference Smith HS, Smith JM, Seidner P. Opioid-induced nausea and vomiting. Ann Palliat Med. 2012;1(2):121–9.PubMed Smith HS, Smith JM, Seidner P. Opioid-induced nausea and vomiting. Ann Palliat Med. 2012;1(2):121–9.PubMed
38.
go back to reference Coca-Perraillon M. Local and global optimal propensity score matching. SAS Global Forum 2007, April 16–19, 2007, Orlando, FL. Coca-Perraillon M. Local and global optimal propensity score matching. SAS Global Forum 2007, April 16–19, 2007, Orlando, FL.
39.
go back to reference Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130–9.CrossRefPubMed Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130–9.CrossRefPubMed
40.
go back to reference Wells N, Pasero C, McCaffery M. Improving the quality of care through pain assessment and management. In: Hughes RG, editor. Patient safety and quality: an evidence-based handbook for nurses. Rockville: Agency for Healthcare Research and Quality; 2008. p. 469–97. Wells N, Pasero C, McCaffery M. Improving the quality of care through pain assessment and management. In: Hughes RG, editor. Patient safety and quality: an evidence-based handbook for nurses. Rockville: Agency for Healthcare Research and Quality; 2008. p. 469–97.
41.
go back to reference Suh DC, Kim MS, Chow W, Jang EJ. Use of medications and resources for treatment of nausea, vomiting, or constipation in hospitalized patients treated with analgesics. Clin J Pain. 2011;27(6):508–17.CrossRefPubMed Suh DC, Kim MS, Chow W, Jang EJ. Use of medications and resources for treatment of nausea, vomiting, or constipation in hospitalized patients treated with analgesics. Clin J Pain. 2011;27(6):508–17.CrossRefPubMed
42.
go back to reference Lapane KL, Quilliam BJ, Benson C, Chow W, Kim MS. Gastrointestinal events after opioid treatment in nonmalignant pain: correlates of occurrence and impact on health-related quality of life. J Opioid Manag. 2013;9(3):205–16.CrossRefPubMed Lapane KL, Quilliam BJ, Benson C, Chow W, Kim MS. Gastrointestinal events after opioid treatment in nonmalignant pain: correlates of occurrence and impact on health-related quality of life. J Opioid Manag. 2013;9(3):205–16.CrossRefPubMed
Metadata
Title
Health Care Utilization and Costs Associated with Nausea and Vomiting in Patients Receiving Oral Immediate-Release Opioids for Outpatient Acute Pain Management
Authors
Elizabeth Marrett
Winghan Jacqueline Kwong
Feride Frech
Chunlin Qian
Publication date
01-12-2016
Publisher
Springer Healthcare
Published in
Pain and Therapy / Issue 2/2016
Print ISSN: 2193-8237
Electronic ISSN: 2193-651X
DOI
https://doi.org/10.1007/s40122-016-0057-y

Other articles of this Issue 2/2016

Pain and Therapy 2/2016 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.